Dry Eye Disease And The Jenvis Dry Eye Report Diagnosis Tool: A Literature Review with Emphasis On African Populations Authors: Tebatso Pertunia Tsotetsi, Pheagane Motsime William Nkoana, Mahwash Khan Published: 2026 ABSTRACT AbstractBackgroundDry Eye Disease (DED) is a multifactorial ocular surface disorder characterized by tear film instability, ocular discomfort, and visual disturbance. Traditional diagnostic methods often show poor correlation with symptoms and lack reproducibility. The JENVIS Pro Dry Eye Report, integrated with the OCULUS Keratograph 5M, provides a structured, non-invasive, and multimodal approach to DED diagnosis in line with TFOS DEWS II recommendations.AimTo review Dry Eye Disease and evaluate the diagnostic role of the JENVIS Pro Dry Eye Report, with particular emphasis on its application and limited utilization in African populations.MethodsA literature review was conducted using Google Scholar, PubMed, and ScienceDirect, focusing on studies published between 2017 and 2025. Search terms included Dry Eye Disease, JENVIS Pro Dry Eye Report, OCULUS Keratograph 5M, non-invasive diagnostics, and tear film instability. Studies addressing DED epidemiology, risk factors, diagnostic methods, and JENVIS-related parameters such as non-invasive tear break-up time, tear meniscus height, and meibography were included.ResultsSeventy sources were reviewed, including peer-reviewed articles and relevant grey literature. The evidence supports the JENVIS Pro Dry Eye Report as a reliable and reproducible diagnostic system that integrates objective clinical signs with subjective symptom assessment. While the tool is widely recognised internationally, its clinical use in African populations remains limited, with most regional studies relying on traditional diagnostic techniques such as Schirmer’s test and fluorescein tear break-up time.ConclusionThe JENVIS Pro Dry Eye Report offers a comprehensive and objective approach to DED diagnosis compared with conventional methods. Expanding its application in African clinical settings may improve diagnostic consistency, patient education, and evidence-based management of Dry Eye Disease.ContributionThe study provides background and benefits of the use of JENVIS Dry Eye report in diagnosing DED and advocates for its use due to its benefits.Keywords: dry eye disease, JENVIS Pro Dry Eye Report, OCULUS Keratograph 5M, artificial intelligence, tear film instability Introduction According to the Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II), Dry Eye Disease (DED) is a multifactorial disease of the ocular surface characterized by a loss of tear film homeostasis and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.1 DED also known as keratoconjunctivitis sicca or ocular surface disease, is a multifactorial condition characterized by a loss of tear film homeostasis.1 Stapleton et al2 estimate a 5 to 50% worldwide prevalence of DED, which varies by geographical region. It is associated with symptoms such as irritation, visual disturbances, and inflammation, significantly impairing quality of life.3,4 Traditional diagnostic methods, including Schirmer’s test, tear break-up time (TBUT) test, and ocular surface staining, are invasive and often poorly correlated with patient-reported symptoms.5 The JENVIS Pro Dry Eye Report is a comprehensive diagnostic and documentation system developed to streamline the clinical evaluation of DED and to provide clinicians with a structured approach to both diagnosis and management.6 Its foundation lies in the work of the JENVIS Research Group, which originated at the Ernst-Abbe University of Applied Sciences in Jena, Germany. Since its establishment in the early 2000s, the group has specialised in ocular surface and tear film research, contributing significantly to the understanding of dry eye pathophysiology, diagnostic testing, and the clinical challenges of differentiating between subtypes of the disease.7,8 The first JENVIS Dry Eye Report was introduced in 2009 as a standardized template for assessing DED. This tool aimed to harmonize clinical practice by systematically combining objective diagnostic findings, such as TBUT, ocular surface staining, Schirmer testing, and meibography, with subjective symptom reporting through validated questionnaires. This innovation was particularly valuable, as DED is recognized as a multifactorial disease in which objective signs often do not correlate directly with patient symptoms. By providing a unified format, the original report improved both the reliability of diagnosis and the comparability of findings across clinical and research settings.7 In response to growing clinical demand and evolving international guidelines, the tool was further refined and re-launched as the JENVIS Pro Report in 2017. This upgraded version was built upon the original framework by incorporating additional diagnostic modalities, integrating updated cut-off values, and aligning more closely with the TFOS DEWS II recommendations published that same year.3,8 Unlike its predecessor, the JENVIS Pro Report goes beyond data collection using an algorithmic process to generate a structured summary that not only supports an evidence-informed diagnosis but also helps classify patients into relevant DED subtypes, such as Aqueous-Deficient Dry Eye (ADDE) or Evaporative Dry Eye (EDE). The JENVIS Pro Report also enhances clinical practice by presenting findings in a clear, visualized format that facilitates communication with patients, promotes patient education, and supports shared decision-making. Its design minimizes the risk of overlooking essential diagnostic steps, ensuring a holistic evaluation of the ocular surface. The historical evolution from the 2009 JENVIS Report to the 2017 JENVIS Pro Report highlights the group’s responsiveness to advances in dry eye research and international consensus.8 Today, the JENVIS Pro Report stands as both a clinical documentation aid and a practical decision-support tool, representing the JENVIS Group’s long-standing commitment to bridging the gap between research and routine clinical eye care.3,8 This review aims to describe DED and the use of JENVIS Pro Dry Eye Report as a comprehensive diagnostic tool, with particular emphasis on its relevance and underutilization in African populations. Methods This literature review was conducted to evaluate the diagnostic role of the JENVIS Pro Dry Eye Report in DED, with particular attention to its application in African clinical contexts. A comprehensive search of academic databases, including Google Scholar, PubMed, and ScienceDirect, was undertaken for studies published between 2017 and 2025. The timeframe was selected to align with the publication of the TFOS DEWS II reports, which standardized diagnostic definitions and methodologies in DED research.2–4 Search terms included combinations of “Dry Eye Disease”, “JENVIS Pro Dry Eye Report”, “Oculus Keratograph 5M,” “non-invasive diagnostics”, “tear film instability”, and “ocular surface disease”.7–9 Boolean operators (AND/OR) were applied to optimize retrieval. Articles were included if they reported on DED epidemiology, risk factors, diagnostic methods, or clinical applications of JENVIS components such as non-invasive tear break-up time (NIKBUT) test, tear meniscus height (TMH) test, or meibography.9–13 Particular attention was given to studies conducted in African populations to evaluate the extent of JENVIS Pro utilization and identify gaps in diagnostic practices within the region. Only English-language studies were considered. A total of 70 references were reviewed, comprising 53 peer-reviewed scholarly articles and 18 web-based sources. Of the peer-reviewed studies, several addressed DED epidemiology and risk factors, while others focused on the clinical performance of the JENVIS Pro Dry Eye Report and associated non-invasive diagnostic modalities. The evidence indicates that JENVIS Pro provides a reliable, reproducible, and patient-friendly approach to diagnosis, consistent with TFOS DEWS II recommendations. Its integrated, multimodal assessment of both subjective symptoms and objective signs positions it as superior to single-parameter tests. Nevertheless, its adoption in African clinics remains limited, with most regional studies still relying on traditional diagnostic methods such as Schirmer’s test and TBUT, which may partly explain the wide variability in reported prevalence rates. Epidemiology of DED In a meta-analysis study in children by Zou et al,14 DED generally has a higher prevalence (34.6%) when diagnosed using symptoms and a lower prevalence (16.6%) when diagnosed by clinical diagnostic criteria. The global Bayesian modelling study further found a 9.12% prevalence when diagnosing DED by symptoms, while diagnosing DED with clinical techniques found a 35.2% prevalence.15 The TFOS DEWS II criteria, on the other hand, promote combining clinical signs and presenting symptoms, where a prevalence of 29.5% was reported.15 There is a gross variation in DED prevalence per country or region, which is brought by the methods and techniques used and the regional exposures.16 Less stringent measures yield lower prevalences.17 From Table 1, reported African prevalence of DED ranges from 21.2% in a population-based study in South Africa18 to 82.3% in a hospital-based cohort from the similar country.19 Ethiopian community-based studies reported prevalence rates of 40.1%20 and 49.4%,21 while a Nigerian hospital-based study found 32.0%.22 A meta-analysis pooling African data estimated an overall prevalence of 42%, with South Africa contributing higher estimates (54.9%).23 The majority of the studies in Africa used TBUT and Schirmer tests as diagnostic techniques, and the findings18,20–23 differed drastically from those that additionally used the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire.19 These studies relied on TBUT and Schirmer testing, and often combined with symptom questionnaires, which may partly explain the wider variation. Table 1Prevalence of DED by RegionCountry/AreaFirst AuthorPopulation/SettingAge (yrs)Sample SizePrevalenceDiagnostic CriteriaAFRICANigeriaLong et al22Hospital staffAdults—32.0%TBUT, Schirmer, symptomsEthiopiaZeleke et al20Community adults (Goro District)Adults—40.1%TBUT, SchirmerEthiopiaYibekal et al21Community adults (South Gondar Zone)Adults—49.4%TBUT, SchirmerSouth AfricaNaidoo et al19Population-based (Durban, KZN)Adults—21.2%TBUT, SchirmerSouth AfricaNaidoo et al18Hospital-based (KZN attendees)≥18—82.3%SPEED; TBUT/Schirmer subsetAfrica (multi)Akowuah et al23Meta-analysis (multiple African countries)Adults—42.0% pooled; SA ~54.9%MixedASIASaudi ArabiaJareebi et al24General population27±101,06277.0%QuestionnairesSaudi Arabia (Western)Zarban et al25University students21–2540274.6%OSDIOmanShah et al26Clinic-based<30 and >3012742.5%Questionnaires; TBUT; SchirmerMalaysia (Kuala Lumpur)Mohd‑Ali et al27Population-based18–6085014.6%McMonnies questionnaireChina (Hong Kong)Lam et al28Population-based46–552358.0%OSDI>55; Schirmer<10China (Taiwan)Lin et al29Population-based≥651,36133.7%>1 symptom/positive signNORTH AMERICAUSA (Beaver Dam, WI)Moss et al30Population cohort48–91 (65±10)3,72214.4%Self‑reported historyUSA (Women’s Health Study)Schaumberg et al31Female cohort49–8936,9957.8%History of diagnosis/severe symptomsUSA (NHWS)Farrand et al32National Health & Wellness Survey≥18—6.8% diagnosed (8.8% F; 4.5% M)Self‑reported diagnosisUSA (Claims database)Yazdani et al33Pharmetrics claimsN/A≈10 mil0.48% (1997); 0.39% (1998)ICD codes/punctal occlusionUSA (general)Stapleton et al2TFOS DEWS II epidemiology reviewAdults—Range ~5–14%MixedSpain (Salnés Eye Study)Viso et al34Population-based≥402,35311.0%OSDI; TBUT; Schirmer; stainingFranceMalet et al35Population-basedAdults—~20% symptomaticQuestionnaire (OSDI-like)NetherlandsVehof et al36Population/Twins UK-related analysesAdults—≈9–10% symptomaticQuestionnaire (DEQ/OSDI)UKThe EPIC‑Norfolk Eye Study (subset)37Population-basedAdults—≈14% symptomsQuestionnaireMIDDLE EASTSaudi ArabiaJareebi et al24Population27±101,06277.0%QuestionnairesSaudi ArabiaZarban et al25University students21–2540274.6%OSDIOmanShah et al26Clinic<30 and >3012742.5%Questionnaires; TBUT; SchirmerIranHashemi et al38Population-based (Tehran/Shahroud)Adults—20–34%Questionnaire ± signsAustralia (Blue Mountains)Chia et al39Population-based≥501,07516.6% (≥1 symptom); 15.3% (≥3)Symptom-basedAustralia (Tasmania)Hirani et al40Population-based (older adults)≥50—≈10–20% symptomsQuestionnaireNew ZealandWolffsohn et al10Regional summaryAdults—≈9–20% rangeMixed Prevalence of DED by Region Table 1 presents that the Middle East prevalence of DED is the highest globally. Two Saudi Arabian studies, one in a community-based24 and another in a university population-based,25 found almost similar findings of 77% and 74.6% prevalence rates using questionnaires, respectively. In Oman, a clinic-based study reported 42.5% when combining questionnaire responses with TBUT and Schirmer testing.26 Iranian population-based studies estimated prevalence between 20% and 34%, depending on the diagnostic threshold applied.38,41 Similar to the Iranian study, the Qatarian study reported a similar range of 20% to 32% prevalence rates.42 Three-Asian based studies found fair prevalences of DED of 33.7% in Taiwan,29 14.6% in Malaysia,27 and 8.0% in China.28 The Taiwanese study included an elderly population as compared to the others. Stricter diagnostic tools were used, and the findings may further suggest that lifestyle factors such as high digital device use among younger populations and age-related changes in tear physiology contribute to regional variation. Four US-based studies were included (see Table 1), with 14.4% prevalence rate reported for the Beaver Dam study,30 7.8% for the Women’s Health Study,31 6.8% for the National Health and Wellness Survey,32 and 5 to 14% for the TFOS DEWS II33 across various populations of different age groups. In Europe, four population-based studies were included with 20.0% prevalence rate in France,2 14% in the UK-based EPIC-Norfolk Eye study,35 11.0% in Spain,34 and 9.0 to 10.0% in the Netherlands.37 Two German-based studies found prevalences of DED at 21.6% in an adult population, with women exhibiting a higher prevalence rate36 and another between 20–23 persons be 1000.43 Münch et al43 also reported negative effects of DED on the health-related QoL and fatigue levels. Most studies in these regions used questionnaires supplemented with signs and found higher prevalence rates consistently in women and older adults. In Australia and Oceania (see Table 1), the Melbourne Visual Impairment Project reported 16.3% prevalence rate based on Schirmer testing, 10.8% using Rose Bengal staining, 8.6% by TBUT, and 1.5% using fluorescein staining.44 The Blue Mountains Eye Study reported 16.6% prevalence based on at least one symptom and 15.3% when requiring three or more symptoms.39 More recent studies confirm a prevalence of around 10 to 20%, particularly among older adults.10,40 Variations in various methods of diagnosis evidently present different prevalence rates. African and Middle Eastern studies tend to report higher prevalence compared to North America, Europe, and Oceania, largely due to hospital-based sampling, questionnaire-based diagnosis, or inclusion of high-risk populations. Conversely, population-based studies in Europe, the US, and Oceania which used both clinical tests and questionnaires generally reported lower prevalence rates. Across all regions, older age and female sex are consistently associated with higher DED prevalence, highlighting universal demographic risk factors. These strikingly high figures are likely explained by harsh environmental conditions (heat, aridity, dust storms), combined with behavioral exposures such as high screen time and widespread use of air-conditioning. Additionally, student cohorts dominate some Middle Eastern studies, which may inflate prevalence due to intense near work. The Middle East emerges from the table as a hotspot for DED, highlighting the need for more population-representative surveys and preventive interventions. The variation reflects differences in sampling frames: population-based cohorts provide more conservative estimates, while hospital- and clinic-based samples inevitably report higher values due to health-seeking bias. Environmental factors unique to Africa and also the Middle East, such as dust, arid climate, high UV exposure, and systemic comorbidities, are plausible contributors to the elevated prevalence. Risk Factors of DED DED is influenced by a combination of demographic, lifestyle, medical, and environmental factors. Age and female gender are consistently associated with higher prevalence, likely due to hormonal changes and age-related decline in tear production.36,45–49 Diabetes increases risk through lacrimal and meibomian gland dysfunction (MGD),50 while hypertension and certain medications can impair tear film stability.51,52 Sleep disturbances, smoking, and alcohol use further exacerbate ocular surface dryness.50,52–54 Behavioral and environmental exposures, including prolonged screen time, occupational hazards, contact lens wear, and harsh climates, contribute to DED development.26,46,54–56 Socioeconomic status and education level also affect prevalence, and limited awareness is linked to higher risk.57–59 Additionally, MGD is a leading cause of evaporative DED.26 Overall, DED results from the interplay of intrinsic physiological changes, external environmental stressors, and lifestyle behaviors, highlighting the need for individualized preventive and management strategies. A summary of the major risk factors and their mechanisms is presented in Table 2. Table 2Risk Factors of DEDRisk FactorDescription/MechanismReferencesAgeTear production declines with age; age-related changes in the ocular surface contribute to higher DED prevalence.Lu et al48 Schaumberg et al49 Uchino et al51 Moon et al47 Vehof et al36Gender (Female)Hormonal changes increase susceptibility; women report higher severityNichols et al45 Viso et al34 Uchino et al51 Moon et al47DiabetesAlters lacrimal and meibomian gland function, affecting tear qualityIglesias et al50HypertensionCan impair tear production; some antihypertensives contribute to DEDUchino et al52Medication UseCertain drugs (antihistamines, diuretics, antidepressants) reduce tear production.Olaniyan et al51Sleep DisturbancesPoor sleep reduces blink rate and ocular surface hydration.Zhan et al53 Iglesias et al50SmokingCigarette smoke damages meibomian glands and destabilizes the tear film.Alshamrani et al54AlcoholDehydration and altered tear production increase the riskUchino et al52Screen Time/Digital Device UseProlonged use reduces blink rate, increases tear evaporationUchino et al55 Yang et al56 Uchino & Schaumberg60OccupationProlonged screen use, environmental exposureShah et al26 Alshamrani et al54Contact Lens WearLens material and wearing habits disrupt the tear film, causing mechanical irritation.Alshamrani et al54 Uchino et al52Socioeconomic Status (SES)Lower SES is linked to reduced access to healthcare and awarenessMilla´n et al57Education LevelHigher education is associated with better awareness and management.Ferrero et al58 Ahn et al59Meibomian Gland Dysfunction (MGD)Dysfunction of the meibomian glands leads to evaporative dry eyeShah et al26Environmental FactorsHarsh climates, dust, heat, and aridity contribute to tear film instability.Alshamani et al54 Uchino et al52 Risk Factors of DED Pathophysiology of DED The pathophysiology of DED involves multiple interrelated mechanisms that disrupt the stability and function of the tear film and ocular surface. The tear film consists of three primary layers: the outer lipid layer produced by the meibomian glands, the middle aqueous layer secreted by the lacrimal glands, and the inner mucin layer derived from conjunctival goblet cells.3 Disruption in any of these layers can lead to one of two major subtypes of DED: aqueous-deficient dry eye (ADDE) and evaporative dry eye (EDE), each with distinct mechanisms. The two subtypes may also present together to form mixed DED.2,61 ADDE results from insufficient secretion of the aqueous component of the tear film due to dysfunction or damage to the lacrimal glands.3,61 This may be caused by autoimmune diseases such as Sjögren’s syndrome, age-related degeneration, systemic medications, or post-surgical and radiation-related damage.2 The resulting reduction in tear volume increases tear film osmolarity, which initiates an inflammatory cascade involving the release of cytokines such as IL-1, IL-6, and TNF-α, leading to epithelial cell damage, goblet cell loss, and further destabilization of the tear film.1,10 This chronic inflammation perpetuates a cycle of tear deficiency and ocular surface damage. Clinically, ADDE is characterized by reduced Schirmer’s test values, low tear meniscus height, and increased ocular surface staining.3 EDE, on the other hand, is caused by excessive evaporation of the tear film, most commonly due to MGD.3,4 In MGD, meibomian glands may be obstructed, atrophic, or secrete poor-quality lipids, compromising the lipid layer and accelerating evaporation of the aqueous layer.1 Environmental exposures such as wind, pollution, and low humidity, as well as behavioral factors like prolonged digital screen use and decreased blink rate, further contribute to tear evaporation.60 As with ADDE, the hyperosmolar tear film in EDE triggers ocular surface inflammation and epithelial cell damage, which leads to goblet cell loss and further tear film instability.62 EDE patients may present with normal Schirmer values but reduced NIKBUT, visible meibomian gland dropout on meibography, and signs of lid margin inflammation.63 Despite their distinct origins, both ADDE and EDE converge on a common final pathway involving tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory dysfunction, creating a vicious cycle that exacerbates disease progression.1,4 Understanding these mechanisms is critical for accurate diagnosis and effective, personalized treatment, particularly when using modern diagnostic systems like the JENVIS Pro Dry Eye Report integrated in the OCULUS Keratograph 5M, which combines subjective and objective parameters to assess the specific subtype and severity of DED.63 Diagnosing DED Traditional Methods Diagnosing DED presents considerable challenges due to the heterogeneity of symptoms and the often-poor correlation between patients’ subjective complaints and objective clinical signs.3 Traditional diagnostic methods for DED include the Schirmer test, the Phenol Red Thread Test, TBUT test, Tearscopy, and TMH test. Schirmer Test The Schirmer test is one of the oldest and most employed methods, involving the placement of filter paper strips in the lower conjunctival sac to measure tear production. It primarily evaluates tear quantity. Its advantages include simplicity, low cost, and wide availability. However, it is invasive, may provoke reflex tearing, and its results can vary significantly depending on technique and patient tolerance, thereby limiting reproducibility and diagnostic accuracy.3,7 Phenol Red Thread Test This test uses a phenol red impregnated cotton thread placed in the lower fornix, where the colour change indicates the measure of the tear volume and also tear pH. Like the Schirmer test, it assesses tear quantity but is less invasive and faster, often producing less reflex tearing. Its limitations include variability influenced by environmental conditions and less widespread clinical use, which has restricted its adoption.3,10 Tear Break-Up Time Test The TBUT test, which is also called the fluorescein break-up time test, is a key diagnostic test used to assess tear film stability and quality. TBUT is typically measured by instilling fluorescein dye into the tear film and observing the interval between a complete blink and the first appearance of a dry spot under a slit lamp.10 There are derivatives of the test which vary depending on the equipment and method used. Tear Thinning Time test measures the time taken for optical distortion to appear on the tear-film on a keratometer as the tear film thins, while Non-Invasive Break Up Time (NIBUT) test measures the time the tear film breaks, also using the keratometer.10,11 NIKBUT on the other hand is performed using keratographs without fluorescein instillation, providing an objective, reproducible, and non-invasive measurement of tear stability, though it requires specialized but costly equipment, and results can vary across devices and operators.11 Tearscopy Tearscopy uses a slit-lamp biomicroscope or tear film analyzer to visualize the tear film lipid layer and its interference patterns. It focuses on tear quality and is particularly useful in assessing MGD and EDE. Its benefits lie in its direct assessment of the lipid layer, but it is subjective, requires examiner expertise, and lacks universal standardization.3,7,10 Tear Meniscus Height Test The TMH test assesses the tear basal volume at the lower lid margin using a slit-lamp biomicroscope. This is a non-invasive but it can also be performed with the use of fluorescein staining. However, outcomes can be influenced by blinking patterns and examiner judgment, and it lacks precision compared with more advanced imaging techniques.3,7 While these traditional diagnostic techniques have been widely used to detect dry eye, they often lack sensitivity and specificity.11,64,65 One of the most persistent challenges in DED diagnosis is the poor correlation between patient-reported symptoms and clinical signs. Many patients report significant discomfort despite having normal test results, while others with clear clinical signs may be asymptomatic.11,64,65 They are also limited by their invasive nature and the potential for reflex tearing, which can distort results. Moreover, clinician subjectivity plays a major role in interpreting outcomes, introducing variability and potentially leading to underdiagnosis or misdiagnosis.7,11 Therefore, there is a growing need for more advanced diagnostic tools that can objectively assess the tear film, provide reproducible results, and integrate symptom evaluation with clinical measurements.11 To overcome these limitations, modern clinical optometry has increasingly adopted advanced, non-invasive, and objective diagnostic technologies. Novel Techniques Recent advances in DED diagnostics emphasize objective, non-invasive, and technology-driven methods. Artificial intelligence (AI) is now applied to meibography, TBUT, and TMH measurements, providing reproducible and less observer-dependent outcomes.12 Optical devices such as the Tear Film Imager allow high-resolution mapping of tear film layers and real-time monitoring of stability.9 Color interferometry has also gained traction, enabling visualization and quantitative assessment of the lipid layer thickness and spread, offering insight into tear film stability and evaporation risk.9 Similarly, assessments of tear film viscosity and rheological behavior have emerged, highlighting the importance of physical tear film properties in maintaining ocular surface health and their diagnostic potential in differentiating aqueous-deficient and evaporative dry eye.1 Advanced Anterior Segment Ocular Coherence Tomography (AS-OCT) and in vivo confocal microscopy, combined with AI, further facilitate early detection of corneal nerve alterations and inflammatory activity.13 Dynamic video-based techniques additionally track blink-related tear film behavior, offering a more functional assessment of ocular surface dynamics.66 Collectively, these technologies promise earlier, more precise, and standardized diagnosis of DED, though barriers remain regarding cost, accessibility, validation, and translation into routine practice.11 Despite these advancements, the JENVIS Dry Eye Pro implements an integrative and unified system in DED diagnosis with non-invasive, objective, multiple parameters, including the TMH, NIKBUT, conjunctival and bulbar redness scan, and the meibomian gland imaging, the meiboscan.9 Several peer-reviewed studies67,68 using the Keratograph 5M or earlier Keratograph models support the components of JENVIS Pro, confirming that TMH and NIKBUT have acceptable repeatability and reproducibility in both healthy and DED populations. A comparative study of the Keratograph 5M with the IDRA ocular surface analyzer showed good agreement in measurements of NIBUT and TMH in DED eyes. This suggests that the Keratograph/K5M-based tools like JENVIS are consistent with other contemporary devices.69 Additional benefits of the JENVIS Dry Eye Report in the DED diagnosis are its multimodal approach as compared to those that use single-parameter methods, the non-invasive dye-free modality, and further, the repeatability and reproducibility.70 Hence, available empirical evidence supports most of the component measures in the JENVIS Pro Dry Eye Report (such as TMH, NIKBUT, meibomian gland imaging) as valid, reproducible, non-invasive markers of DED. The integration of these into a structured, automated, and non-invasive report gives JENVIS Pro Dry Eye Report theoretical and practical superiority over traditional single-test methods. There is, however, a greater need for targeted clinical studies to validate the composite scoring against standard diagnostics, including variable populations and longitudinal, and to assess correlation with patient-reported symptom burdens. Factors That are Barriers to JENVIS Pro Dry Eye Report Use One major obstacle is the high initial equipment cost and the need for compatible hardware and software infrastructure, which may be out of reach for many clinics with limited budgets.35 In addition, the system requires regular maintenance, software updates, and technical support to ensure optimal performance needs, which may not be met in under-resourced healthcare settings.5 Limited technical expertise among clinicians and staff unfamiliar with advanced imaging and AI-based diagnostic tools presents another challenge, as these systems demand specific training to operate and interpret results effectively.32 Moreover, in many resource-scarce healthcare systems, basic eye care services such as refractive correction, cataract surgery, and management of infectious diseases are prioritized over specialized diagnostics, leading to limited funding and policy support for newer technologies.24 Addressing these barriers will require not only financial investments to support the procurement of JENVIS systems but also targeted training programs and capacity building for clinicians and support staff. Collaborations between academic institutions, government agencies, and industry partners can provide sustainable models for technology adoption and training.32 Furthermore, policy frameworks that incorporate evidence-based strategies for integrating advanced diagnostics into national eye health plans are essential to ensure that these tools are accessible to those who need them most.2 By systematically addressing these challenges, it will be possible to harness the full potential of the JENVIS Dry Eye Report to improve the accuracy of DED diagnosis and contribute to more robust, locally relevant data on the burden of DED in Africa. Future Directions and Research Needs Future research should focus on validating AI-based diagnostic tools like JENVIS in African settings by establishing normative values and evaluating long-term treatment outcomes. Additionally, studies should explore the integration of tele-optometry platforms for remote diagnosis and monitoring of DED, which may be particularly beneficial in rural or resource-limited areas. There is also a need for interventional research evaluating whether JENVIS-guided management strategies lead to better clinical outcomes compared to traditional approaches. Lastly, cost-effectiveness analyses would help determine the feasibility of widespread implementation of such tools in public healthcare systems. Conclusion DED is a multifactorial condition that remains a major cause of ocular discomfort and visual disturbance worldwide. Traditional diagnostic methods, such as Schirmer’s test and TBUT, continue to be widely used but are limited by invasiveness, variability, and poor correlation with patient symptoms. The evidence drawn from 70 references in this review highlights that the JENVIS Pro Dry Eye Report provides a more comprehensive, objective, and reproducible approach to DED diagnosis, integrating both symptom-based questionnaires and non-invasive clinical measurements such as NIKBUT, TMH, conjunctival redness, and meibography. This multimodal system aligns with international TFOS DEWS II guidelines and enhances diagnostic accuracy compared with single-test methods. However, despite its demonstrated reliability and global uptake, its utilisation in African clinical settings remains sparse, with most research in the region still relying on conventional diagnostic approaches. Expanding the application of the JENVIS Pro system in African clinics has the potential to improve diagnostic consistency, patient education, and evidence-based management of DED, thereby addressing both local and global gaps in dry eye care. Disclosure The authors report no conflicts of interest in this work. References